InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,612.40
(
0.01%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.92
(
-0.67%
)
Bitcoin
63,000.02
(
-0.26%
)
Post# of 251747
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 828
Posts 119588
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: lgonber post# 189362

Monday, 03/30/2015 11:18:21 AM

Monday, March 30, 2015 11:18:21 AM

Post# of 251747
Teva is desperate to fix its overreliance on one product—Copaxone—for about 50% of its profits. (This is a separate issue from generic competition for Copaxone.)

ABBV had a similar problem with Humira, but that’s well on its way to being rectified by growth in V-Pak and Imbruvica.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up